Copanlisib (BAY 80-6946)，又称库潘尼西，是ATP竞争性的泛I类PI3K抑制剂，具有抗肿瘤活性，在非霍奇金淋巴瘤和慢性淋巴细胞白血病的I/II期临床试验中具有潜力，作用于PI3Kα/δ/β/γ的IC₅₀分别为0.5 nM、0.7 nM、3.7 nM和6.4 nM。

参考文献

[1] Liu N, et al. BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013 Nov;12(11):2319-30.

[2] Elster N, et al. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib. Breast Cancer Res Treat. 2015 Jan;149(2):373-83.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。